Nigeria Breast Cancer Therapeutics Market Analysis Report [2022-30] I Insights10

Nigeria Breast Cancer Therapeutics Market Analysis

$ 3999

The Nigeria breast cancer therapeutics market is projected to grow from $16 Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022-2030 due to the adoption of western lifestyles leading to increased prevalence of breast cancer. The market is segmented by therapy, by cancer type, and by distribution channel. Emzor, May & Baker, and Bristol-Myers Squibb are some of the major players in the Nigeria breast cancer therapeutics market.

ID: IN10NGPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Nigeria AUTHOR: Parul Choudhary

Buy Now

Nigeria Breast Cancer Therapeutics Market Executive Analysis

The Nigeria breast cancer therapeutics market size is at around $16 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. Out of the $45 Bn overall budget for the 2023 fiscal year in Nigeria, $2.6 Bn was allotted to the health sector. The service-wide vote includes $0.18 Bn for the health sector. Included in this are $0.15 Bn for Global Alliance for Vaccines and Immunization (GAVI)/vaccination; $0.016 Bn for counterpart money, which comprises a global fund and a health return to GAVI; and $0.0097 Bn for military retirees covered by the National Health Insurance Scheme (NHIS). From the $1.82 Bn allotted to the health sector in 2022 and the $1.20 Bn given in 2021, the 2023 budget represents a huge rise. The recurring health budget increased by 25.54 %, while capital expenditures increased by 94.83 % from the 2022 budget.

Breast cancer cases in Nigeria have historically been low, but they are currently rising as a result of urbanization and lifestyle modifications. It accounts for about 23% of all cancer diagnoses and roughly 18% of fatalities in the nation, making it the main cause of cancer mortality at the moment. The epidemiological transformation occurring in these nations, the rising prevalence of established risk factors including obesity and Hormone Replacement Therapy (HRT), as well as the rising utilization of early diagnosis and screening techniques, are responsible for this. In some parts of Nigeria, modified radical mastectomy (MRM), with its accompanying plexopathy, lymphedema, and bridle scar, is the most common surgical procedure. Targeted and multimodal therapeutic combinations are not widely accessible or inexpensive. Modern drugs and equipment are also not available in healthcare institutions.

Market Dynamics

Market Growth Drivers

Adoption of western lifestyles leading to obesity which in turn results in a higher incidence of breast cancer and increased enrolment in the National Health Insurance Scheme (NHIS) leading to lower breast cancer patients' out-of-pocket expenses are the main market drivers of Nigeria's breast cancer therapeutics market.

Market Restraints

The expansion of the Nigeria breast cancer therapeutics market is being constrained by a lack of oncological facilities in Nigeria and a lack of funding for breast cancer treatment from government organizations. The availability of labor, the cost of and access to cancer medications, the lack of comprehensive health insurance programs for breast cancer, and other associated factors are also impeding Nigeria's breast cancer therapeutics market expansion.

Competitive Landscape

Key Players

Swiss Pharma (NGA)
Fidson (NGA)
Emzor (NGA)
May & Baker (NGA)
Bristol-Myers Squibb
Eli Lilly
Halozyme
Merck

Healthcare Policies and Regulatory Landscape

In the past, the National Health Insurance Scheme (NHIS) was called the National Health Insurance Authority (NHIA). It is a corporate entity that the federal government of Nigeria established under the NHIA Act 2022 to increase access to high-quality, reasonably priced healthcare for all Nigerians. The Law requires NHIA to do a number of things, including ensuring that health insurance is obligated for all citizens and legal residents of Nigeria, promoting, regulating, and integrating health insurance schemes across the nation, and enhancing and utilizing private sector involvement in the delivery of healthcare services. The ultimate goal is to guarantee that all Nigerians have access to Universal Health Coverage (UHC).

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.